Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus L Andersen

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Cell|September 13, 2014
A dual program for translation regulation in cellular proliferation and differentiationHila Gingold, Disa Tehler, Nanna R Christoffersen, et al.
Molecular Oncology|March 12, 2015
Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistanceNiels F Jensen, Jan Stenvang, Mette K Beck, et al.
Nature|December 1, 2006
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpointsJirina Bartkova, Nousin Rezaei, Michalis Liontos, et al.
Nature Communications|November 3, 2016
Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effectPaula Lopez-Serra, Miguel Marcilla, Alberto Villanueva, et al.
Nature Communications|April 5, 2014
A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effectPaula Lopez-Serra, Miguel Marcilla, Alberto Villanueva, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2024
Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patientsAmanda Frydendahl, Jesper Nors, Mads H Rasmussen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2026
Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C TrialIsmail Gögenur, Tobias F Justesen, Line S Tarpgaard, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Cell|September 13, 2014
A dual program for translation regulation in cellular proliferation and differentiationHila Gingold, Disa Tehler, Nanna R Christoffersen, et al.
Molecular Oncology|March 12, 2015
Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistanceNiels F Jensen, Jan Stenvang, Mette K Beck, et al.
Nature|December 1, 2006
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpointsJirina Bartkova, Nousin Rezaei, Michalis Liontos, et al.
Nature Communications|November 3, 2016
Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effectPaula Lopez-Serra, Miguel Marcilla, Alberto Villanueva, et al.
Nature Communications|April 5, 2014
A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effectPaula Lopez-Serra, Miguel Marcilla, Alberto Villanueva, et al.
European Journal of Cancer (Oxford, England : 1990)|September 24, 2024
Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patientsAmanda Frydendahl, Jesper Nors, Mads H Rasmussen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2026
Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C TrialIsmail Gögenur, Tobias F Justesen, Line S Tarpgaard, et al.
Pageof 7